

Express Mail Label No.: EV 317 172 250 US

Date: February 10, 2004

Docket No.: VPI/00-130-07 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bebbington, et al.

DIVISIONAL OF: 10/034,019 EXAMINER: Tamthom Ngo Truong

FILING DATE: Herewith ART UNIT: 1624

FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

February 10, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the National Application;
- within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).

A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the

APPLICANTS: **Bebbington, et al.**
U.S.S.N.: **Not Yet Assigned**

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-130-07 DIV US.

Respectfully submitted,



Andrea L.C. Robidoux, Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6731
Fax: (617) 444-6483

| | | |
|--|------------------------|----------------------|
| Modified Form 1449/PTO | Application Number | Not Yet Assigned |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | Filing Date | February 10, 2004 |
| (use as many sheets as necessary) | First Named Inventor | David Bebbington |
| | Group Art Unit | 16124 |
| | Examiner Name | Tamthom Ngo Truong |
| | Attorney Docket Number | VPI/00-130-07 DIV US |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------------------|-------------|--|-------|-----------|----------------------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
| | A1* | 5,710,158 | 20-Jan-1998 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|---------------------------------------|-------------------------------------|---------------------|--------------------|
| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes No |
| | B1* | WO 01/25220 | Kinetix Pharmaceuticals Inc. | 12-Apr-2001 | |
| | B2* | WO 00/78757 | Shionogi Bioresearch Corp. | 28-Dec-2000 | |
| | B3* | WO 00/39101 | Astrazeneca UK Limited | 06-Jul-2000 | |
| | B4* | WO 00/21955 | Zeneca Limited | 20-Apr-2000 | |
| | B5* | WO 02/18346 | Pfizer Products Inc. | 07-Mar-2002 | |
| | | | | | |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/034,019, filed December 20, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|